Craig-Hallum lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $17 from $23 and keeps a Buy rating on the shares. Despite the disappointing guidance for 2025, the company expects strong demand to continue, with 2,800-3,000 patients expected to initiate therapy in 2025, the analyst tells investors in a research note. The firm thinks guidance may prove conservative as it assumes persistency rates continue to worsen and the company is not able to drive improvement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Piper Sandler cuts Avadel Pharmaceuticals price target, says staying bullish
- Avadel Pharmaceuticals price target lowered to $21 from $25 at H.C. Wainwright
- Avadel Pharmaceuticals price target lowered to $19 from $22 at Needham
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
- Avadel Pharmaceuticals Projects Robust Growth for LUMRYZ